Please Wait.....
Report
Global Peripheral Neuropathy Treatment Market Report and Forecast 2023-2031
Market Report I 2023-04-15 I 147 Pages I EMR Inc.
Global Peripheral Neuropathy Treatment Market Report and Forecast 2023-2031
Global Peripheral neuropathy Treatment Market Outlook
The global peripheral neuropathy treatment market reached a value of about USD 737 million in 2022 and is expected to grow at a CAGR of 3.7% during the forecast period of 2023-2031. With the rising prevalence of chronic diseases, which increase the risk of peripheral neuropathy in chronic disease patients, the market is expected to reach USD 1022 million by 2031.
Peripheral neuropathy Treatment Market: Introduction
The peripheral neuropathy treatment market refers to the market for the diagnosis and treatment of peripheral neuropathy, which is a condition that affects the nerves outside of the brain and spinal cord, leading to symptoms such as pain, numbness, and tingling. The condition can be caused by a variety of factors, including diabetes, alcoholism, and autoimmune disorders, and can have a significant impact on the quality of life of affected individuals.
The global peripheral neuropathy treatment market is highly competitive, with key players focusing on research and development activities to develop innovative products and strengthen their market position. The market is characterized by the presence of both global and regional players. The increasing prevalence of peripheral neuropathy, the growing demand for effective treatment options, and the availability of advanced healthcare infrastructure in developed countries are expected to drive the growth of the market during the forecast period.
Peripheral Neuropathy Epidemiology
Peripheral neuropathy is a common condition that affects millions of people worldwide, with the prevalence of the condition increasing with age. The exact cause of peripheral neuropathy is unclear, but it is believed to be a combination of genetic and environmental factors, such as diabetes, alcoholism, and autoimmune disorders. According to a study published in the Journal of the Peripheral Nervous System, the prevalence of peripheral neuropathy in the United States is estimated to be between 2.4% and 7.8%, with the highest prevalence observed in individuals aged 60 years or older.
The prevalence of peripheral neuropathy is expected to increase in the coming years due to the aging population and the rising incidence of diabetes and other chronic diseases. These factors are expected to drive the demand for peripheral neuropathy treatment in the coming years.
Peripheral Neuropathy Treatment Market Segmentations
The market can be categorised into type, treatment method, diagnosis, end user, treatment channel, and major region.
Market Breakup by Type
- Diabetic Peripheral Neuropathy
- Chemotherapy-Induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- HIV/AIDS Associated Peripheral Neuropathy
Market Breakup by Treatment Method
- Pharmacological Therapies
? Pain Relievers
? Anti-Seizure Medications
? Anti-Depressants
- Non-Pharmacological Therapies
? Transcutaneous Electrical Nerve Stimulation
? Plasma Exchange
? Others
- Others
Peripheral Neuropathy Treatment Market Breakup by End User
- Hospitals and Clinics
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Treatment Channel
- Public
- Private
Peripheral neuropathy Treatment Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
Peripheral neuropathy Treatment Market Scenario
The global peripheral neuropathy treatment market is expected to witness significant growth during the forecast period of 2023-2031. The market is driven by factors such as the increasing prevalence of peripheral neuropathy, the growing demand for effective treatment options, and the availability of advanced healthcare infrastructure in developed countries. Additionally, the rising incidence of chronic diseases such as diabetes and cancer, which are leading causes of peripheral neuropathy, is also contributing to the growth of the market.
North America dominates the peripheral neuropathy treatment market, followed by Europe and the Asia Pacific. The market in North America is driven by the high prevalence of peripheral neuropathy and the availability of advanced healthcare infrastructure. The market in Europe is also expected to grow significantly, with key players focusing on research and development activities to develop innovative products. The market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about peripheral neuropathy and the rising healthcare expenditure in the region.
Key Players in the Global Peripheral Neuropathy Treatment Market
The report gives an in-depth analysis of the key players involved in the peripheral neuropathy treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Abbott Laboratories
- Bristol Myers Squibb Co
- Novartis AG
- Eli Lilly and Company
- Pfizer Inc.
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- F. Hoffmann-La Roche Ltd
- Cipla Ltd.
- Lupin Ltd
- Dr. Reddy's Laboratories
- RxFunction, Inc.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Peripheral Neuropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Peripheral Neuropathy Treatment Market
6.1 Global Peripheral Neuropathy Treatment Market Overview
6.2 Global Peripheral Neuropathy Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Peripheral Neuropathy Treatment Market Historical Value (2016-2022)
6.2.1.2 Global Peripheral Neuropathy Treatment Market Forecast Value (2023-2031)
6.3 Global Peripheral Neuropathy Treatment Market by Type
6.3.1 Market Overview
6.3.1.1 Diabetic Peripheral Neuropathy
6.3.1.2 Chemotherapy-Induced Peripheral Neuropathy
6.3.1.3 Idiopathic Peripheral Neuropathy
6.3.1.4 HIV/AIDS Associated Peripheral Neuropathy
6.4 Global Peripheral Neuropathy Treatment Market by Therapeutics Method
6.4.1 Market Overview
6.4.1.1 Pharmacological Therapies
6.4.1.1.1 Pain Relievers
6.4.1.1.2 Anti-Seizure Medications
6.4.1.1.3 Anti-Depressants
6.4.1.2 Non-Pharmacological Therapies
6.4.1.2.1 Transcutaneous Electrical Nerve Stimulation
6.4.1.2.2 Plasma Exchange
6.4.1.2.3 Others
6.4.1.3 Others
6.5 Global Peripheral Neuropathy Treatment Market by End User
6.5.1 Market Overview
6.5.1.1 Hospitals And Clinics
6.5.1.2 Retail Pharmacy
6.5.1.3 Online Pharmacy
6.6 Global Peripheral Neuropathy Treatment Market by Treatment Channel
6.6.1 Public
6.6.2 Private
6.7 Global Peripheral Neuropathy Treatment Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.1.1 Historical Trend (2016-2022)
6.7.1.1.2 Forecast Trend (2023-2031)
6.7.1.2 Europe
6.7.1.2.1 Historical Trend (2016-2022)
6.7.1.2.2 Forecast Trend (2023-2031)
6.7.1.3 Asia Pacific
6.7.1.3.1 Historical Trend (2016-2022)
6.7.1.3.2 Forecast Trend (2023-2031)
6.7.1.4 Latin America
6.7.1.4.1 Historical Trend (2016-2022)
6.7.1.4.2 Forecast Trend (2023-2031)
6.7.1.5 Middle East and Africa
6.7.1.5.1 Historical Trend (2016-2022)
6.7.1.5.2 Forecast Trend (2023-2031)
7 North America Peripheral Neuropathy Treatment by Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2 Canada
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8 Europe Peripheral Neuropathy Treatment by Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2 Germany
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 France
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 Italy
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Peripheral Neuropathy Treatment by Treatment Market
9.1 China
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2 Japan
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 India
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 ASEAN
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 Australia
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Peripheral Neuropathy Treatment by Treatment Market
10.1 Brazil
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2 Argentina
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Mexico
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Peripheral Neuropathy Treatment by Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Nigeria
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges and Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Peripheral Neuropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter's Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Abbott Laboratories
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Bristol Myers Squibb Co
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Eli Lilly and Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Pfizer Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 GlaxoSmithKline Plc
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Merck and Co. Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 F. Hoffmann-La Roche Ltd
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Cipla Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Lupin Ltd
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Dr. Reddy's Laboratories
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 RxFunction, Inc.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Recommendations and Discussion
17 Global Peripheral Neuropathy Treatment Drugs Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security